Literature DB >> 19505822

Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1).

Sundar Neelakantan1, Shama Nasim, Monica L Guzman, Craig T Jordan, Peter A Crooks.   

Abstract

A series of aminoparthenolide analogs (6-37) were synthesized and evaluated for their anti-leukemic activity. Eight compounds exhibited good anti-leukemic activity with LD(50)'s in the low microM range (1.5-3.0microM). Compounds 16, 24 and 30 were the most potent compounds in the series, causing greater than 90% cell death at 10microM concentration against primary AML cells in culture, with LD(50) values of 1.7, 1.8 and 1.6microM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505822     DOI: 10.1016/j.bmcl.2009.05.092

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  75 in total

1.  Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.

Authors:  Vikas Tyagi; Hanan Alwaseem; Kristen M O'Dwyer; Jessica Ponder; Qi Ying Li; Craig T Jordan; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2016-06-16       Impact factor: 3.641

2.  Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia.

Authors:  Zaineb A F Albayati; Venumadhav Janganati; Zheng Chen; Jessica Ponder; Philip J Breen; Craig T Jordan; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2016-12-26       Impact factor: 3.641

3.  Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization.

Authors:  Joshua N Kolev; Kristen M O'Dwyer; Craig T Jordan; Rudi Fasan
Journal:  ACS Chem Biol       Date:  2013-11-08       Impact factor: 5.100

4.  Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer.

Authors:  Emilie Viennois; Bo Xiao; Saravanan Ayyadurai; Lixin Wang; Peng G Wang; Quan Zhang; Yue Chen; Didier Merlin
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

Review 5.  Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones.

Authors:  Yulin Ren; Jianhua Yu; A Douglas Kinghorn
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

6.  Potential Anticancer Agents Characterized from Selected Tropical Plants.

Authors:  Yulin Ren; Esperanza J Carcache de Blanco; James R Fuchs; Djaja D Soejarto; Joanna E Burdette; Steven M Swanson; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2019-03-04       Impact factor: 4.050

7.  Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis.

Authors:  Hanan Alwaseem; Benjamin J Frisch; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2017-08-08       Impact factor: 3.641

8.  Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell.

Authors:  Gen Ba; Zhongyan Hua; Ning Xu; Simeng Zhang; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Cell Cycle       Date:  2020-05-13       Impact factor: 4.534

Review 9.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

10.  KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells.

Authors:  Yong Xu; Fang Fang; Sumitra Miriyala; Peter A Crooks; Terry D Oberley; Luksana Chaiswing; Teresa Noel; Aaron K Holley; Yanming Zhao; Kelley K Kiningham; Daret K St Clair; William H St Clair
Journal:  Cancer Res       Date:  2013-05-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.